A Pilot Study of Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD) With Sirolimus for the Treatment of Adult Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies.

Trial Profile

A Pilot Study of Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD) With Sirolimus for the Treatment of Adult Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Sirolimus (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Folinic acid; Methotrexate; Rituximab; Vincristine
  • Indications Acute lymphoblastic leukaemia; Adult T-cell leukaemia-lymphoma; B cell lymphoma; Burkitt's lymphoma; Mantle-cell lymphoma; T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Apr 2014 Trial status changed from active, no longer recruiting to completedas reported by ClinicalTrials.gov.
    • 22 Aug 2013 Planned End Date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 02 Aug 2011 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top